Modafinil is a prescription wake-promoting medication used in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder. In OSA, it treats excessive sleepiness rather than the underlying airway obstruction.
Studies lasting 40 weeks in narcolepsy and 12 months in CPAP-treated OSA provide the clearest prospective evidence on continued use. They found that many patients maintained improvements in excessive sleepiness and tolerated ongoing treatment, but both were open-label extension studies rather than long-term placebo-controlled trials.
For someone asking whether modafinil has been shown to be safe for five, ten or twenty years of continuous use, the evidence is much less complete. A 2026 systematic review concluded that long-term efficacy and safety remain to be established.
Key Takeaways
- The best prospective long-term modafinil studies followed patients for about 40 weeks to 12 months, not for many years.
- In those extension studies, wakefulness benefits were maintained for many patients, but some stopped because of adverse effects.
- Tolerance did not develop across the 40-week narcolepsy study as a whole, although later research confirms that it can occur in some individual patients.
- Current US labeling warns about cardiovascular effects, psychiatric symptoms, serious skin or hypersensitivity reactions, misuse and important drug interactions.
- Evidence from medically treated sleep-disorder populations cannot establish the safety of years of nonmedical modafinil use in otherwise healthy people.
What Counts as Long-Term Modafinil Use?
There is no single research cutoff that defines “long-term” modafinil use.
Randomized controlled trials have generally been much shorter than the years for which some patients may take the medication. A 2026 systematic review of modafinil for narcolepsy found that the randomized evidence still comes largely from older, relatively short trials and concluded that long-term safety and efficacy remain insufficiently established.
The main prospective extension studies reach approximately 40 weeks in narcolepsy and 12 months in OSA. Those studies can tell us more about continued treatment over months, but they cannot establish that uninterrupted treatment over five, ten or twenty years has the same safety profile.
What Do Long-Term Studies of Modafinil Show?
Two open-label extension studies provide much of the direct prospective evidence.
| Study | Population | Duration | Main findings | Main limitation |
|---|---|---|---|---|
| Mitler et al. (2000) | 478 adults with narcolepsy who entered extension studies after earlier trials | 40 weeks | Wakefulness benefit was maintained; 71% completed treatment; 9% discontinued because of adverse events | Open-label extension |
| Hirshkowitz & Black (2007) | 266 CPAP-treated patients with OSA and residual excessive sleepiness | 12 months | Improvements in sleepiness were maintained; 66% completed; six patients had significant blood-pressure increases | Open-label extension |
40 Weeks in People With Narcolepsy
Mitler and colleagues followed 478 adults with narcolepsy who entered two 40-week open-label extension studies after completing earlier controlled trials.
Participants received 200 to 400 mg of modafinil per day, and about 75% received 400 mg. Improvements in excessive daytime sleepiness were maintained through week 40. The most common treatment-related adverse events were headache in 13%, nervousness in 8% and nausea in 5%.
A total of 341 patients, or 71%, completed the studies. Forty-three, or 9%, discontinued because of adverse events. The investigators reported no evidence of tolerance developing across the study population during the 40 weeks.
Because the extension population came from patients enrolled in preceding controlled trials, its tolerability findings may not generalize perfectly to everyone beginning modafinil treatment.
12 Months in CPAP-Treated Obstructive Sleep Apnea
Hirshkowitz and Black followed 266 patients with OSA who were receiving CPAP but still had excessive sleepiness. Participants received modafinil for up to 12 months.
One hundred seventy-five patients, or 66%, completed the study. Improvements in excessive sleepiness were maintained at months 3, 6, 9 and 12.
The most frequently reported adverse events were infection in 11.3%, headache in 9.4% and nervousness in 9.0%. Serious adverse events occurred in 13 patients. Mild bradycardia and severe syncope in one patient were considered possibly related to modafinil.
Six patients had significant increases in blood pressure, five of whom already had a history of hypertension.
Is Modafinil Proven Safe to Take for Years?
Modafinil has not been studied in long-duration randomized trials that establish safety over several years.
The 2026 systematic review of modafinil for narcolepsy included nine studies, with five randomized trials involving 997 adults in the meta-analysis. The authors found that the randomized evidence remained dominated by older trials and concluded that long-term efficacy and safety still need to be established.
The 40-week and 12-month extension studies extend the evidence beyond those shorter trials, but their open-label design makes them less able than randomized controlled trials to identify uncommon adverse effects or determine whether an event is actually caused by modafinil.
This is why “people have taken modafinil for a year in studies” and “modafinil has been proven safe for years” are not equivalent statements.
Does Modafinil Become Less Effective Over Time?
The 40-week narcolepsy extension did not find evidence of tolerance developing across the study population. Patients maintained improvements in excessive sleepiness without an overall pattern suggesting that the medication progressively stopped working.
Tolerance can occur in individual patients, however.
A 2023 study enrolled 41 people with narcolepsy who had already developed tolerance to modafinil, described by the researchers as loss of efficacy accompanied by increasing dose requirements. The study tested a treatment strategy involving pitolisant-supported drug holidays.
Because the researchers deliberately selected patients who already had tolerance, the study cannot tell us how often tolerance develops among all people who take modafinil.
The evidence therefore supports a limited conclusion: tolerance is not inevitable, but it can occur.
Can Long-Term Modafinil Use Cause Dependence or Addiction?
Tolerance refers to a declining effect at the same dose, while physical dependence refers to physiological adaptation that can produce withdrawal after stopping. Misuse or addiction involves a different pattern of problematic drug use.
In one placebo-controlled trial, no withdrawal symptoms were reported during 14 days of observation after nine weeks of modafinil treatment, although sleepiness returned in people with narcolepsy. That study does not establish what happens after years of continuous treatment.
Modafinil nevertheless has recognized abuse potential. In the United States it is a Schedule IV controlled substance. Current labeling states that it can produce psychoactive and euphoric effects and advises clinicians to watch for signs of misuse or abuse, including increasing doses or drug-seeking behavior.
MedlinePlus also warns that modafinil may be habit-forming and says it should not be taken in larger doses, more frequently or for longer than prescribed.
Can Modafinil Affect Blood Pressure or the Heart During Long-Term Use?
In a pooled analysis of six randomized trials involving 1,529 participants treated for up to 12 weeks, clinically significant increases in systolic or diastolic blood pressure occurred in fewer than 1% of modafinil-treated patients. New clinically meaningful ECG abnormalities were also rare.
Current US labeling adds another useful measure. In short-term controlled trials, 2.4% of patients receiving modafinil required new or increased antihypertensive medication compared with 0.7% receiving placebo. Among patients with OSA, the figures were 3.4% and 1.1%, respectively. The label states that increased monitoring of heart rate and blood pressure may be appropriate and advises caution in people with known cardiovascular disease.
The 12-month OSA extension adds longer follow-up but no placebo comparison. Six participants had clinically significant blood-pressure increases, and five already had hypertension.
A large observational study using three US healthcare claims databases found no increased myocardial-infarction risk among modafinil users and no consistent increase in cardiovascular hospitalization. In a subgroup of patients with OSA who had previously experienced a stroke, however, modafinil use was associated with a higher risk of another stroke in one analysis, with a hazard ratio of 1.96 and a 95% confidence interval of 1.02 to 3.76.
Because that study was observational, the subgroup finding cannot establish that modafinil caused the additional strokes.
Available studies have not identified a consistent overall increase in major cardiovascular events, but the evidence is not strong enough to rule out long-term cardiovascular risk in every patient.
Can Long-Term Modafinil Affect Mental Health?
Current US labeling documents psychiatric adverse effects from both controlled trials and postmarketing reports.
In controlled trials, psychiatric symptoms that led to discontinuation more often with modafinil than placebo included anxiety in 1%, nervousness in 1%, and less frequently insomnia, confusion, agitation and depression.
Postmarketing reports have included mania, delusions, hallucinations, suicidal ideation and aggression, with some cases requiring hospitalization. The label advises caution in people with a history of psychosis, depression or mania and says clinicians should consider stopping modafinil if psychiatric symptoms emerge.
A 2026 systematic review of published case reports and case series identified 24 patients with modafinil- or armodafinil-associated psychosis. Some cases occurred at therapeutic doses. Case reports cannot establish how often the reaction occurs or prove that modafinil caused every episode, but they show why new hallucinations, delusions or major behavioral changes should be taken seriously.
What Do We Know About the Liver and Kidneys?
Long-term modafinil studies have not been designed to rule out every form of cumulative liver or kidney injury.
Current US labeling provides clearer evidence about patients who already have severe organ impairment.
In people with severe hepatic impairment, modafinil clearance was reduced by about 60% and steady-state concentrations were approximately doubled. The label therefore calls for the dose to be reduced in severe hepatic impairment.
In a single-dose study in people with severe chronic renal failure, kidney impairment did not significantly alter modafinil concentrations, but exposure to modafinil acid, an inactive metabolite, increased about ninefold.
Those findings describe how organ impairment changes drug handling. They do not answer whether taking modafinil for many years causes cumulative liver or kidney damage in otherwise healthy organs.
What Serious Reactions Can Occur During Modafinil Treatment?
Current US labeling warns about serious rash, including Stevens-Johnson syndrome, as well as angioedema, anaphylaxis and multiorgan hypersensitivity reactions.
Most reported serious rashes occurred within one to five weeks after treatment began, although isolated cases have occurred after longer treatment, including around three months. The label states that treatment duration cannot be used to predict whether a new rash will become serious.
The Medication Guide says to stop modafinil and call a doctor immediately or seek emergency help for symptoms including:
- rash, hives, mouth sores, blistering or peeling skin
- swelling of the face, eyes, lips, tongue or throat
- trouble swallowing or breathing
- fever with other signs of a serious hypersensitivity reaction.
These reactions are important treatment risks, but they should not be described as evidence that toxicity steadily accumulates with every additional year of modafinil use.
Does Long-Term Modafinil Affect Sleep?
Insomnia is a recognized adverse effect of modafinil. Current patient labeling also warns that taking it too close to bedtime may make it harder to fall asleep.
In pooled randomized trials lasting up to 12 weeks, modafinil did not significantly alter measured sleep architecture compared with placebo.
Those trials were much shorter than years of continuous treatment, so they cannot answer every question about long-term sleep architecture.
For someone taking modafinil chronically, persistent difficulty sleeping is therefore relevant to treatment review even if daytime wakefulness has improved.
What About Taking Modafinil for Years for Focus or Productivity?
The principal long-term studies involved people being treated for diagnosed sleep disorders: narcolepsy and CPAP-treated OSA with residual excessive sleepiness.
Their results cannot automatically be applied to healthy people taking modafinil for studying, work performance or cognitive enhancement.
The evidence is even less applicable when someone takes higher-than-prescribed doses or combines modafinil with other psychoactive substances. The 2026 review of modafinil-associated psychosis specifically identified off-label cognitive-enhancement use as a setting in which caution is warranted.
Long-term medical experience with modafinil should therefore not be treated as proof that prolonged nonmedical use is safe.
Who May Need More Careful Review During Long-Term Treatment?
Current US labeling calls for greater caution or monitoring in people with cardiovascular disease or a history of psychosis, depression or mania. It also advises clinicians to watch for misuse or abuse, especially in people with a history of drug or stimulant abuse.
Severe hepatic impairment requires dose reduction, while geriatric patients may require lower doses and closer monitoring because modafinil elimination can be reduced with age.
Pregnancy and pregnancy planning also require review. Current US labeling states that modafinil may cause fetal harm based on animal data.
What Drug Interactions Matter During Long-Term Use?
Modafinil affects several drug-metabolizing pathways, so a medication list that was safe when treatment began may need review when other medicines are added or removed.
Current US labeling warns that steroidal contraceptives may become less effective during modafinil treatment and for one month after modafinil is stopped. It also identifies interactions involving cyclosporine and medicines metabolized through CYP2C19, including phenytoin, diazepam, propranolol and omeprazole.
Patients taking warfarin may require more frequent INR monitoring, and the label advises caution when modafinil is used with monoamine oxidase inhibitors.
What Should Be Reviewed During Long-Term Modafinil Treatment?
Current labeling supports continued attention to several areas during treatment:
- whether excessive sleepiness persists despite treatment
- blood pressure and heart rate when increased cardiovascular monitoring is appropriate
- new or worsening psychiatric symptoms
- increasing doses or other signs of misuse or abuse
- changes in other medications that could interact with modafinil.
A medication that remains effective and tolerable after several months may still need reassessment if its benefits decline, new adverse effects appear or other health conditions and medications change.
So, Is Long-Term Modafinil Use Safe?
The most defensible conclusion depends on the time horizon.
For treatment lasting months to about one year, prospective studies provide some reassuring evidence. Many patients maintained improvements in excessive sleepiness, and no clear pattern of progressively accumulating toxicity emerged in the main 40-week and 12-month extension studies.
For continuous use over several years or decades, the evidence is much weaker. Long-duration randomized safety trials are lacking, and a 2026 systematic review concluded that long-term efficacy and safety remain to be established.
That uncertainty does not mean long-term modafinil is necessarily unsafe. It means the available evidence cannot support a blanket claim that indefinite treatment is risk-free. Continued treatment has to be judged in the context of its ongoing benefit, adverse effects, cardiovascular and psychiatric risk, misuse potential, drug interactions and the individual patient’s health.
Frequently Asked Questions
How long can you safely take modafinil?
There is no research-based maximum duration that applies to every patient. Prospective extension studies have followed modafinil treatment for 40 weeks in narcolepsy and 12 months in CPAP-treated OSA, while evidence over several years is much less rigorous.
Is it safe to take modafinil every day?
Daily treatment was used in the major long-term extension studies, and many participants remained on treatment for months to about one year. Those studies do not prove that daily use is risk-free over many years.
Does modafinil stop working if you take it every day?
Not necessarily. The 40-week narcolepsy extension found no evidence of tolerance developing across the study population, but a later study confirms that tolerance can occur in some patients. How frequently it occurs is not well established.
Is modafinil bad for your heart long term?
Available studies have not shown a consistent overall increase in major cardiovascular events, but blood-pressure effects occur and the long-term evidence has limitations. Current US labeling says increased monitoring of heart rate and blood pressure may be appropriate and advises caution in people with cardiovascular disease.
Can long-term modafinil use cause addiction?
Modafinil is a Schedule IV controlled substance in the United States and has recognized abuse potential. Current labeling advises clinicians to watch for increasing doses and drug-seeking behavior. A nine-week trial did not identify withdrawal symptoms during 14 days after stopping, but that does not establish what happens after years of use.
Does modafinil damage the brain if taken long term?
Long-duration human studies have not been designed to answer whether years of modafinil exposure affect every aspect of brain health. The available evidence therefore cannot establish either progressive brain damage or complete neurological safety over decades.
Should you take breaks from modafinil?
There is not enough evidence to recommend routine drug holidays for everyone taking modafinil. A 2023 study tested pitolisant-supported breaks specifically in patients who had already developed tolerance, so its findings should not be generalized to all modafinil users.
References
Hirshkowitz, M., & Black, J. (2007). Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: A 12-month, open-label extension study. CNS Drugs, 21(5), 407–416. https://doi.org/10.2165/00023210-200721050-00004
Kaplan, S., Goehring, E. L., Melamed-Gal, S., Nguyen-Khoa, B. A., Knebel, H., Jones, J. K., & Cappelleri, J. C. (2018). Modafinil and the risk of cardiovascular events: Findings from three US claims databases. Pharmacoepidemiology and Drug Safety.
Mann, G. S., Ramakrishnan, M., Pakkam, M. L., Sufiyan, N., Kukadiya, R., & Girigosavi, K. B. (2026). An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy. Sleep Medicine: X, 11, 100185. https://doi.org/10.1016/j.sleepx.2026.100185
Mitler, M. M., Harsh, J., Hirshkowitz, M., & Guilleminault, C. (2000). Long-term efficacy and safety of modafinil (PROVIGIL) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Medicine, 1(3), 231–243. https://doi.org/10.1016/S1389-9457(00)00031-9
Roth, T., Schwartz, J. R. L., Hirshkowitz, M., Erman, M. K., Dayno, J. M., & Arora, S. (2007). Evaluation of the safety of modafinil for treatment of excessive sleepiness. Journal of Clinical Sleep Medicine, 3(6), 595–602.
Sato, Y., Sakuma, A., & Tomita, H. (2026). Modafinil-associated psychosis: A systematic review of case characteristics and management strategies. Therapeutic Advances in Psychopharmacology, 16, 20451253261446554. https://doi.org/10.1177/20451253261446554
U.S. National Library of Medicine. (2025). Modafinil tablets: Prescribing information. DailyMed.
U.S. National Library of Medicine. (n.d.). Modafinil. MedlinePlus.
Winter, Y., Lang, C., Kallweit, U., Apel, D., Fleischer, V., Ellwardt, E., & Groppa, S. (2023). Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy. Sleep Medicine, 112, 116–121. https://doi.org/10.1016/j.sleep.2023.10.005
This article is for general information and is not a substitute for advice from a healthcare professional who knows your medical history and current medications.
